Current and Future Management of Immune Thrombocytopenia — Video Program

Faculty

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of immune thrombocytopenia.

LEARNING OBJECTIVES

• Evaluate factors, including age, comorbidities, bleeding history/risk, lifestyle and personal preferences, that influence the decision to initiate active therapy for immune thrombocytopenia (ITP), and counsel patients regarding personalized initial treatment recommendations.
• Appraise available guidelines concerning the recommended duration of corticosteroid use as initial therapy for ITP, and identify patients with insufficient response or relapse after steroids for whom a change of treatment may be warranted.
• Understand long-term efficacy and safety data with FDA-approved second- and later-line treatments for ITP, and consider this information in the selection and sequencing of therapy for patients with persistent/chronic disease.
• Comprehend the scientific rationale for the evaluation of Bruton tyrosine kinase (BTK) inhibition as a therapeutic approach for ITP, and appreciate early-phase efficacy and safety findings with novel oral BTK inhibitors.
• Appreciate emerging Phase III efficacy findings with oral BTK inhibitor therapy for patients with persistent or chronic ITP refractory to prior treatment, and prepare for the potential clinical availability of this novel therapeutic approach.
• Discern the side effects and toxicities associated with available and investigational therapies employed in the care of patients with ITP, and identify strategies to manage and mitigate them.
• Recollect available research and ongoing trials evaluating other novel agents and strategies under investigation for ITP, and counsel appropriately selected patients about participation in active research protocols.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and a post-test, enables the participant to earn up to 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ITPThinkTank2024/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Hanny Al-Samkari, MD
Classical Hematologist and Clinical Investigator
The Peggy S Blitz Endowed Chair in Hematology/Oncology
Co-Director, Hereditary Hemorrhagic Telangiectasia Center
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: Agios Pharmaceuticals Inc, Alnylam, Alpine Immune Sciences, Amgen Inc, argenx, Novartis, Pharmacosmos, Sanofi, Sobi; Contracted Research: Agios Pharmaceuticals Inc, Amgen Inc, Novartis, Sobi, Vaderis Therapeutics AG.

James B Bussel, MD
Professor Emeritus
Weill Cornell School of Medicine
New York, New York

Advisory Committees: argenx, Novartis, Sanofi, Sobi, UCB, Vertex Pharmaceuticals Incorporated; Consulting Agreements: Janssen Biotech Inc, Rallybio.

Professor Nichola Cooper, MD, MA, FRCP, FRCPath
Professor of Immune Haematology
Director, Centre for Immune Thrombocytopenia
Co-Lead, Immunology NIHR BRC Theme
Department of Immunology and Inflammation
Faculty of Medicine
Imperial College London
Hammersmith Hospital Campus
London, United Kingdom

Advisory Committees and Speakers Bureaus: Amgen Inc, Grifols, Novartis, Sanofi, Sobi, Takeda Pharmaceutical Company Limited; Consulting Agreements: Amgen Inc, Grifols, Novartis, Sanofi, Sobi; Contracted Research: argenx, Novartis, Rigel Pharmaceuticals Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from Novartis and Rigel Pharmaceuticals Inc.

Release date: April 2025
Expiration date: April 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr Al-Samkari

Ayad et al. Long-term risk of developing immune thrombocytopenia and hematologic neoplasia in adults with mild thrombocytopenia. Blood 2022;140(26):2849-52. Abstract

Cuker A et al. Overuse of corticosteroids in patients with immune thrombocytopenia (ITP) between 2011 and 2017 in the United States. eJHaem 2023;4(2):350-7. Abstract

Goncalves I et al. Thrombosis in patients with immune thrombocytopenia: Incidence, risk, and clinical outcomes. Res Pract Thromb Haemost 2024;8(1):102342. Abstract

 

Dr Bussel

Bussel J et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am Hematol 2018;93(7):921-30. Abstract

Bussel JB et al. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol 2019;94(5):546-53. Abstract

Kuter DJ et al. Long-term efficacy and safety with oral Bruton tyrosine kinase inhibitor rilzabrutinib in patients with immune thrombocytopenia. ISTH 2024;Abstract OC 65.1.

 

Prof Cooper

Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. eBioMedicine 2022;76:103820. Abstract

Kuter DJ, et al. Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia. N Engl J Med 2022;386(15):1421-31. Abstract